Fludarabine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Fludarabine: From Hematologic Malignancy Therapy to Plasma Cell Myeloma
One-Sentence Summary
Fludarabine is a purine nucleoside analog chemotherapy drug that is registered in Singapore as an injectable powder. The approved indication text is not available in the data compiled for this report. The TxGNN model predicts it may be useful for plasma cell myeloma, with 31 listed clinical trials and 20 publications in this direction. Most of this evidence concerns fludarabine as a supporting agent (transplant conditioning or CAR-T lymphodepletion), not as a stand-alone myeloma treatment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available (approved indication text is empty in both Singapore licences) |
| Predicted New Indication | Plasma cell myeloma |
| TxGNN Prediction Score | 99.82% |
| Evidence Level | L2 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Fludarabine is a purine nucleoside analog that inhibits DNA synthesis and depletes lymphocytes. Detailed mechanism of action data from DrugBank are not available in the data compiled for this report, so this description relies on the general pharmacology summarised in the repurposing analysis.
In myeloma, fludarabine plays an enabling role rather than a direct antimyeloma one. It is used with busulfan, melphalan or cyclophosphamide as conditioning before allogeneic stem cell transplant. It is also the standard lymphodepletion backbone (with cyclophosphamide) before BCMA-directed CAR-T therapy. Preclinical work reports some direct in vitro and in vivo activity against myeloma cells.
The prediction is therefore reasonable as a supportive-therapy use, but not as evidence that fludarabine alone treats myeloma.
Clinical Trial Evidence
The data include 31 trials linked to plasma cell myeloma. The 10 most relevant are shown below. Most are small, early-phase or mixed-population studies in which fludarabine is part of a regimen.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT06045806 | Phase 3 | Active, not recruiting | 79 | Ide-cel plus lenalidomide maintenance vs lenalidomide alone after transplant (KarMMa-9). Fludarabine is likely used in lymphodepletion, so the evidence is indirect. |
| NCT07764978 | Phase 3 | Recruiting | 750 | BCMA/CD19 CAR-T (AZD0120) consolidation in newly diagnosed myeloma. No results yet. |
| NCT06413498 | Phase 3 | Active, not recruiting | 452 | Anitocabtagene autoleucel vs standard care in relapsed/refractory myeloma. |
| NCT03303950 | Phase 2 | Terminated | 6 | Busulfan, fludarabine, donor transplant and cyclophosphamide in myeloma or myelofibrosis. Data are minimal. |
| NCT01008462 | Phase 2 | Completed | 16 | Sequential autologous and nonmyeloablative haploidentical transplant with a fludarabine-based regimen in lymphoma, myeloma or CLL. |
| NCT00309842 | Phase 2 | Completed | 213 | Cord blood transplant with cyclophosphamide/fludarabine/TBI conditioning in mixed hematologic diseases. |
| NCT00014508 | Phase 2 | Completed | N/A | Autologous transplant followed by mini-allogeneic transplant in myeloma. |
| NCT01658319 | Phase 1 | Completed | 20 | Fludarabine plus methoxyamine (TRC102) in relapsed/refractory hematologic malignancies. |
| NCT03093168 | Phase 1 | Unknown | 10 | BCMA-targeted T cells with fludarabine lymphodepletion. |
| NCT05577000 | Phase 1b | Active, not recruiting | 5 | Anti-BCMA CAR-T in relapsed/refractory myeloma. Fludarabine is a background component. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38483213 | 2024 | Phase 1 trial | Am J Clin Oncol | Bortezomib, fludarabine and melphalan conditioning, with or without total marrow irradiation, before allogeneic transplant in high-risk myeloma. |
| 17310135 | 2007 | Cohort | Bone Marrow Transplant | Reduced-toxicity fludarabine/treosulfan conditioning in 34 myeloma patients before allogeneic transplant. |
| 37701906 | 2023 | Phase 2 study | Leuk Res Rep | Split-dose busulfan, fludarabine and post-transplant cyclophosphamide in 2 myeloma and 4 myelofibrosis patients. Non-relapse mortality at 1 year was 33.3%. |
| 40972962 | 2025 | Real-world study | Transplant Cell Ther | Fludarabine exposure during lymphodepletion was associated with toxicities after ide-cel. |
| 39365257 | 2025 | Cohort | Blood | Standard-of-care cilta-cel in 236 treated patients with relapsed/refractory myeloma. |
| 38659046 | 2024 | Cohort | J Hematol Oncol | 5-year follow-up of LEGEND-2 with LCAR-B38M CAR-T. |
| 35333600 | 2022 | Cohort | J Clin Oncol | Long-term follow-up of combined BCMA and CD19 CAR-T in myeloma. |
| 36690811 | 2023 | Phase 1 | Nat Med | Allogeneic BCMA CAR-T (ALLO-715) after anti-CD52-containing lymphodepletion in 43 patients. |
| 7781758 | 1995 | Report | Eur J Haematol | Fludarabine and plasma cell leukemia (no abstract available). |
| 1415309 | 1992 | Review | Am J Med | Parallels and contrasts between myeloma and CLL. |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN11143P | FLUDARA FOR INTRAVENOUS INJECTION 50 mg/vial | Injection, powder, for solution | Not stated in the available data |
| SIN15030P | FLUDARABINE PHOSPHATE POWDER FOR SOLUTION FOR INJECTION/ INFUSION USP | Injection, powder, for solution | Not stated in the available data |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside analog, lymphodepleting) |
| Myelosuppression Risk | High (significant myelosuppression is a recognised risk of fludarabine) |
| Emetogenicity Classification | Low |
| Monitoring Items | CBC with differential, liver and renal function (fludarabine is renally cleared), and neurological status |
| Handling Protection | Must follow cytotoxic drug handling regulations |
Please also refer to the package insert warnings and precautions.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interacting drugs. Moderate-level interactions include metronidazole, rosuvastatin, simvastatin and tinidazole. Levofloxacin is minor. Others (for example doxycycline, cimetidine, amphotericin B, omeprazole, metformin and morphine) have an unclassified severity.
- Other safety signals from the literature: Higher fludarabine exposure was associated with more toxicity after ide-cel CAR-T (PMID 40972962). Therapy-related MDS/AML has been reported after fludarabine combination chemotherapy (PMID 20962860).
Please refer to the package insert for warnings and contraindications, which are not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Fludarabine is established practice as a conditioning and lymphodepletion agent in myeloma transplant and CAR-T therapy, supported by one or more Phase 2/3 programmes. However, the evidence is indirect and supportive rather than showing stand-alone antimyeloma efficacy. Several larger Phase 3 CAR-T trials are still ongoing, and the small completed myeloma-specific studies are limited.
To proceed, the following is needed:
- Singapore package insert warnings, contraindications and approved indications (the licence indication text is blank)
- Detailed mechanism of action data from DrugBank
- A defined scope limiting use to lymphodepletion and transplant conditioning, not stand-alone myeloma therapy
- Dose adjustment and monitoring plan for renal impairment and myelosuppression
- Review of the interaction list for concurrent medications
Other predictions, for context:
- Indolent plasma cell myeloma (evidence L1, Proceed with Guardrails): supported by completed Phase 3 conditioning trials, but not specific to indolent myeloma.
- Myelodysplastic syndrome (evidence L1, Proceed with Guardrails): fludarabine-based conditioning before allogeneic transplant is established practice, including randomized comparisons (PMID 31606445), but the benefit comes from the transplant platform.
- Unclassified myelodysplastic syndrome: research question only.
- Hyperthyroidism, diabetic nephropathy and several rare genetic disorders: Hold. There is no plausible mechanistic link and no supporting trials. The high scores are likely model artifacts.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.